Abstract
Risankizumab-rzaa (RZA) is a fully human immunoglobulin G monoclonal antibody (Mab) which has fewer immunogenic concerns compared with chimeric Mabs. The pivotal trials of RZA found no significant differences in infusion reactions between drug and placebo. This case illustrates successful transition to subcutaneous RZA following a serious hypersensitivity reaction to intravenous RZA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
